Patents Examined by Albert M Navarro
-
Patent number: 11666526Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.Type: GrantFiled: August 4, 2020Date of Patent: June 6, 2023Assignee: The Foundry, LLCInventors: Mark E. Deem, Hanson Gifford
-
Patent number: 11667980Abstract: Disclosed is a method for controlling the carbon feed to a fed-batch fermenter based on the disturbance of the pH signal following the addition or a limiting substrate.Type: GrantFiled: August 7, 2018Date of Patent: June 6, 2023Assignee: Novozymes A/SInventors: Sjef Cornelissen, Benny Cassells
-
Patent number: 11660319Abstract: The invention provides compositions comprising commensal bacterial strains and organic acids and the uses thereof in the treatment of diseases.Type: GrantFiled: December 13, 2019Date of Patent: May 30, 2023Assignee: 4D Pharma Research LimitedInventors: Imke Elisabeth Mulder, Anna Ettorre, Suaad Ahmed, Parthena Fotiadou, Samantha Yuille, Joseph Roby Iringan Urcia, Helene Savignac
-
Patent number: 11639491Abstract: Provided herein is a method for producing a lyophilized composition of viable cells of Rhizobium bacteria having high viable cell viability, and a lyophilized composition of viable cells of Rhizobium bacteria having desirable long-storage survivability, among others. The lyophilized composition of viable cells of Rhizobium bacteria having high viable cell viability and desirable long-storage survivability can be obtained when a composition containing viable cells of Rhizobium bacteria and more than 10 mass % moisture is lyophilized to bring the moisture content to 10 mass %, and the drying is ended before the moisture content becomes less than 5 mass % so that the composition after the lyophilization contains the viable bacteria and 5 to 10 mass % of moisture.Type: GrantFiled: October 23, 2018Date of Patent: May 2, 2023Assignees: Kumiai Chemical Industry Co., Ltd., K.I Chemical Industry Co., Ltd., Okayama Prefectural GovernmentInventors: Toshinobu Yamazaki, Nobutoshi Myojo, Shingo Hattori, Tatsuya Horiuchi, Akira Kawaguchi, Namiko Kirino
-
Patent number: 11634507Abstract: A method of producing dendritic gold nanoparticles by combining a gold precursor solution, a reducing agent, and a bifunctional peptide having an amine-rich amino acid sequence into a buffered aqueous solution in a single container, and agitating the mixture causing the formation of the dendritic gold nanoparticles having a surface with a positive charge and a second end portion of the bifunctional peptide exposed on the surface of the dendritic gold nanoparticles. The dendritic gold nanoparticles may be used to deliver therapeutic, diagnostic, and/or immunogenic amino acid sequences as portions of the bifunctional peptide.Type: GrantFiled: April 2, 2020Date of Patent: April 25, 2023Assignee: The Board of Regents of the University of OklahomaInventors: Chuanbin Mao, Lin Wang, Penghe Qiu
-
Patent number: 11633434Abstract: Kits and composition comprising: (i) a thermo-responsive hydrogel characterized by a viscosity suitable for hardening after administration on a subject's skin; (ii) a bacterial growth medium; and optionally, (iii) a population of non-pathogenic viable bacteria, are provided. Methods for topically delivering a therapeutic or cosmeceutical agent such as for inhibiting or reducing growth of microorganisms on a subject's skin are further provided.Type: GrantFiled: September 6, 2018Date of Patent: April 25, 2023Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITEDInventors: Boaz Mizrahi, Maayan Lufton
-
Patent number: 11633433Abstract: With the aim of proving an antibacterial composition against oral bacteria and the like capable of inducing Th1 cell proliferation or activation in an intestinal tract, the present inventors have found out that bacteria that suppress colonization and the like of the oral bacteria and the like in the intestinal tract are present in an intestinal microbiota. Moreover, the present inventors have succeeded in isolating intestinal bacteria that suppress intestinal colonization and the like of oral bacteria and the like.Type: GrantFiled: July 18, 2018Date of Patent: April 25, 2023Assignee: KEIO UNIVERSITYInventors: Kenya Honda, Koji Atarashi, Seiko Narushima, Wataru Suda, Masahira Hattori, Munehiro Furuichi, Takaaki Kawaguchi, Keiko Mitobe
-
Patent number: 11618902Abstract: The disclosure discloses Bacillus subtilis for producing N-acetylneuraminic acid and application thereof, and belongs to the field of genetic engineering. The disclosure optimizes the expression levels of key enzymes in N-acetylneuraminic acid synthesis pathways on genome through promoters of different strength, reduces the protein synthesis pressure caused by the expression of enzymes on cells, and further integrates the three N-acetylneuraminic acids in a same Bacillus subtilis engineering strain. Bacillus subtilis with improved N-acetylneuraminic acid production is obtained, and the production reaches 10.4 g/L at the shake flask level, laying a foundation for further improving the NeuAc production from Bacillus subtilis.Type: GrantFiled: February 16, 2021Date of Patent: April 4, 2023Assignee: Jiangnan UniversityInventors: Yanfeng Liu, Long Liu, Xiaolong Zhang, Guocheng Du, Jianghua Li, Jian Chen
-
Patent number: 11613778Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.Type: GrantFiled: January 25, 2021Date of Patent: March 28, 2023Assignee: Roche Sequencing Solutions, Inc.Inventors: Mark Ambroso, Timothy Craig, Matthew DiPietro, Corissa Harris, Marshall Porter
-
Patent number: 11609232Abstract: This invention relates to a method and device for improving the accuracy and performance of detecting or diagnosing sexually transmitted infections (STIs) or STI-causing pathogens. In one embodiment, the present method and device are related to removing one or more interfering molecules such as urea from urine sample, where these interfering molecules alter the performance of Lateral-Flow Immunoassay (LFA). In one embodiment, an aqueous two-phase system (ATPS) embedded entirely within a porous material allows spontaneous phase separation and the target STI-causing pathogens is concentrated in one of the separated phases. In one embodiment, a detection module such as the Lateral-Flow Immunoassay (LFA) is used in connection with other modules so as to detect or diagnose the sexually transmitted infections or the pathogens associated with STIs with an improved performance.Type: GrantFiled: August 30, 2018Date of Patent: March 21, 2023Assignee: PHASE DIAGNOSTICS, INC.Inventors: Yin To Chiu, Garrett Lee Mosley, Brian Sangwoo Lee
-
Patent number: 11609239Abstract: A method and apparatus for locating and selecting a colony of microorganisms on a culture dish and identifying microorganisms in said selected colony using MALDI. The method comprises the automated steps of locating and selecting a colony of microorganisms on a culture dish; obtaining a sample of said selected colony of microorganisms; depositing at least some of said sample of said selected colony of microorganisms on a target plate; and transferring said target plate with said sample in an apparatus for performing MALDI for identification of said sample of said selected colony of microorganisms. A sample of a colony of microorganisms is automatically deposited on a depositing spot such that the sample covers at most approximately half of said one of the depositing spots of the target plate.Type: GrantFiled: November 10, 2020Date of Patent: March 21, 2023Assignee: BD KIESTRA B.V.Inventors: Jetze Botma, Martijn Kleefstra, Tino Walter Van der Zee
-
Patent number: 11603391Abstract: The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.Type: GrantFiled: October 13, 2020Date of Patent: March 14, 2023Assignee: Universiteit Utrecht Holding B.V.Inventors: Hendrik Peter Haagsman, Albert van Dijk, Edwin Johannes Adrianus Veldhuizen
-
Patent number: 11597963Abstract: The invention relates to a method for the identification of a first microorganism potentially secreting an effector compound, said first microorganism thereby having either i. an inhibitory effect on the cell division activity of a second microorganism or ii. an enhancing effect on the cell division activity of a second microorganism, the method comprising: a. providing a cell from a first microorganism which potentially produces an effector compound of interest and a cell from a second detector microorganism; b. introducing both cells into a microdroplet for incubation; c. introducing the microdroplet into a microfluidic system; d. analyzing in said microfluidic system the cell of the second microorganism for the exhibition of an enhanced growth effect or the exhibition of an inhibited growth effect stemming from said effector compound. The invention also relates to a microorganism or effector compound identified by the method according to the invention.Type: GrantFiled: November 9, 2018Date of Patent: March 7, 2023Assignee: BIOMILLENIA SASInventors: Dirk Löffert, Eric Shiue, Aleksander Dajkovic, Guansheng Du
-
Patent number: 11590215Abstract: The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain of Salmonella with at least one DNA molecule comprising at least one expression cassette encoding at least one antigen or at least one fragment thereof; (b) characterizing at least one transformed cell clone obtained in step (a); and (c) selecting at least one of the transformed cell clone(s) characterized in step (b) and further characterizing said at least one selected transformed cell clone. The present invention further relates to a DNA vaccine obtainable by the method according to the present invention.Type: GrantFiled: September 29, 2020Date of Patent: February 28, 2023Assignee: NEC ONCOLMMUNITY ASInventor: Heinz Lubenau
-
Patent number: 11571698Abstract: Provided is an antibacterial agent-containing dried plate having no cracks on an observation surface (a part of the plate corresponding to an observation visual field of a microscope). According to the present embodiment, an antibacterial agent-introduced plate obtained by introducing an antibacterial agent and performing vacuum drying has a recess at an edge of a well, and a microscopic observation portion, which has a surface substantially parallel to a well bottom surface, near the center of the well. The recess is provided between the microscopic observation portion and a side wall of the well, and is lower in height than the microscopic observation portion. Further, at least the bottom surface of the well and the microscopic observation portion are made of a material having a light-transmitting property in order for optical measurement (FIG. 1).Type: GrantFiled: November 2, 2018Date of Patent: February 7, 2023Assignee: HITACHI HIGH-TECH CORPORATIONInventors: Chihiro Uematsu, Yuichi Uchiho, Akira Masuya
-
Patent number: 11567077Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.Type: GrantFiled: March 2, 2016Date of Patent: January 31, 2023Assignee: Oklahoma Medical Research FoundationInventor: Kenneth Smith
-
Patent number: 11560410Abstract: The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.Type: GrantFiled: February 10, 2020Date of Patent: January 24, 2023Assignee: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Richard Malley, Yingjie Lu, Fan Zhang
-
Patent number: 11554144Abstract: Provided are vesicles derived from Enhydrobacter bacteria and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in clinical samples obtained from patients with pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, liver cirrhosis, and diabetes, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited.Type: GrantFiled: March 5, 2019Date of Patent: January 17, 2023Assignee: MD HEALTHCARE INC.Inventor: Yoon-Keun Kim
-
Patent number: 11541081Abstract: Aspects of the invention relate to compositions comprising two or more live bacterial strains for topical administration to the skin, wherein the two or more live bacterial strains are Propionibacterium acnes (P. acnes) bacterial strains, and methods for use.Type: GrantFiled: October 19, 2017Date of Patent: January 3, 2023Assignee: S-Biomedic NVInventors: Bernhard Pätzold, Marc Güell
-
Patent number: 11541110Abstract: Provided are vaccine compositions and methods against Streptococcus pneumoniae. The composition comprises liposomes which have polysaccharides from one or more serotypes and have proteins non-covalently attached to the surface and exposed to the exterior.Type: GrantFiled: October 12, 2018Date of Patent: January 3, 2023Assignee: The Research Foundation for The State University of New YorkInventors: Blaine Pfeifer, Charles Jones